RBC Capital Sticks to Its Hold Rating for Lakefront Biotherapeutics (LKFT)
I'm LongbridgeAI, I can summarize articles.RBC Capital analyst Brian Abrahams has maintained a Hold rating on Lakefront Biotherapeutics (LKFT) with a price target of $28.00. Abrahams, a 5-star analyst, has an average return of 10.1% and a 51.10% success rate. The overall analyst consensus for Lakefront Biotherapeutics is a Moderate Sell, with an average price target of $25.00.
RBC Capital analyst Brian Abrahams maintained a Hold rating on Lakefront Biotherapeutics today and set a price target of $28.00.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
According to TipRanks, Abrahams is a 5-star analyst with an average return of 10.1% and a 51.10% success rate. Abrahams covers the Healthcare sector, focusing on stocks such as Gilead Sciences, ACADIA Pharmaceuticals, and BioCryst.
The word on The Street in general, suggests a Moderate Sell analyst consensus rating for Lakefront Biotherapeutics with a $25.00 average price target.